CARRIER TESTING FOR GENETIC DISEASES

Policy Number: 2019T0586F

Effective Date: July 1, 2019

Table of Contents

CARRIER TESTING FOR GENETIC DISEASES

COVERAGE RATIONALE ........................................ 1
APPLICABLE CODES ........................................... 2
DESCRIPTION OF SERVICES .................................... 2
CLINICAL EVIDENCE ........................................... 3
U.S. FOOD AND DRUG ADMINISTRATION .................... 8
CENTERS FOR MEDICARE AND MEDICAID SERVICES ....... 8
REFERENCES ...................................................... 8
POLICY HISTORY/REVISION INFORMATION .................. 9
INSTRUCTIONS FOR USE ....................................... 9

COVERED RATIONALE

Ashkenazi Jewish Carrier Screening

Ashkenazi Jewish Carrier Screening is proven and medically necessary for evaluating the following:

- Individuals who are seeking prenatal care or planning a pregnancy who have not previously had informative Ashkenazi Jewish Carrier Screening; and
- At least one of the following additional criteria is met:
  - At least one reproductive partner is Ashkenazi Jewish (this individual has at least one Ashkenazi Jewish grandparent); or
  - The reproductive partners have a previously affected child with one of the genetic diseases included in the Ashkenazi Jewish Carrier Screening test and the results of this test will inform a current or future pregnancy; or
  - One or both individuals have a first- or second-degree relative who is affected and the results of this test will inform a current or future pregnancy; or
  - One or both individuals have a first-degree relative with an affected offspring and the results of this test will inform a current or future pregnancy; or
  - One of the reproductive partners is already known to be a carrier for one of the genetic diseases included in the Ashkenazi Jewish carrier screening test and the results of this test will inform a current or future pregnancy.

The following are unproven and not medically necessary due to insufficient evidence of efficacy:

- Carrier testing for any additional genetic diseases as part of Ashkenazi Jewish Carrier Screening
- Ashkenazi Jewish Carrier Screening for all other indications

Expanded Carrier Screening Panel Testing

Expanded Carrier Screening Panel testing is unproven and not medically necessary for all indications due to insufficient evidence of efficacy.

DEFINITIONS

Carrier Screening: Genetic testing that is performed on an individual who does not have any symptoms of a genetic disorder, but may be at risk to have a genetic variant that could be passed to children (ACOG, 2019a).

Expanded Carrier Panel Screening: Multiple genetic disorders that are screened for in one test using a single sample, without regard to ethnicity or family history (ACOG, 2019a).

Panel: A group of laboratory tests that are performed together to assess a body function or disease (Medicare, 2019 and McGraw Hill, 2002).
APPLICABLE CODES

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81412</td>
<td>Ashkenazi Jewish associated disorders (e.g., Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1</td>
</tr>
<tr>
<td>81443</td>
<td>Genetic testing for severe inherited conditions (e.g., cystic fibrosis, Ashkenazi Jewish-associated disorders [e.g., Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (e.g., ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)</td>
</tr>
<tr>
<td>81479</td>
<td>Unlisted molecular pathology procedure</td>
</tr>
</tbody>
</table>

*CPT® is a registered trademark of the American Medical Association*

DESCRIPTION OF SERVICES

Carrier Screening is performed to detect genetic mutations that may increase the risk of a genetic disorder. This testing may impact the reproductive decision-making for parents or prospective parents.

Carrier Screening may be available for autosomal recessive conditions, autosomal dominant less penetrant conditions, X-linked conditions, and certain chromosome abnormalities. In general, Carrier Screening may be performed for conditions that are found in the general population (pan-ethnic), for diseases that are more common in a particular population, or based on family history. For individuals of Ashkenazi Jewish descent (Gross et al., 2008), certain autosomal recessive conditions are more prevalent and many of these disorders are lethal in childhood or associated with significant morbidity.

Diagnostic genetic testing of a heritable disease may also be performed using similar methods as Carrier Screening. It may be medically necessary to use genetic testing to establish a molecular diagnosis when an individual has clinical features, or is at direct risk of inheriting the mutation in question (pre-symptomatic) and the result of the test will directly impact the treatment being delivered.

**Ashkenazi Jewish Carrier Screening**

Carrier Screening for individuals of Ashkenazi Jewish descent is focused on identifying reproductive partners who are at risk to have a child with a disorder that has a higher prevalence in this population. For individuals of Ashkenazi Jewish descent, certain autosomal recessive conditions are more prevalent and many of these disorders are lethal in childhood or associated with significant morbidity. The disorders generally screened in this population are Tay-Sachs, Canavan, Cystic fibrosis, Familial Dysautonomia, Fanconi Anemia, Niemann-Pick type A, Bloom syndrome, Mucolipidosis IV, and Gaucher disease. Since Carrier Screening includes only the most common mutations, a negative screening test result reduces, but does not eliminate, the chance of being a carrier. If an individual has no mutations detected on a Carrier Screening test, the individual still has some remaining risk of being a carrier (Gross et al., 2008; ACOG, 2019).

Ashkenazi Jewish Carrier Screening should include testing for the genetic diseases recommended by American College of Obstetricians and Gynecologists (ACOG) and/or the American College of Medical Genetics (ACMG):

- Tay Sachs disease
- Canavan disease
- Cystic fibrosis
- Familial dysautonomia
- Bloom syndrome
- Fanconi anemia
- Niemann-Pick disease
• Gaucher disease
• Mucolipidosis IV
• Maple Syrup Urine Disease
• Joubert syndrome
• Glycogen storage disease 1A
• Familial hyperinsulinism

Expanded Carrier Screening Panels
For Carrier Screening, new technologies, such as next generation sequencing technology or chromosomal microarray, have created the ability to screen for genetic mutations using genetic Panels instead of single genes. For the purpose of this policy, Expanded Panels are 5 or more genes for non-Ashkenazi Jewish Carrier Screening as they go beyond what is recommended by ACOG for DNA based screening (ACOG 2019a). For Ashkenazi Jewish disorders, Expanded Carrier Screening Panels are those that go beyond the diseases listed above and spinal muscular atrophy screening (ACOG 2019a and ACOG 2019b). Expanded Panels are able to analyze many genes simultaneously, however there is a lack of evidence to establish the clinical utility of gene test Panels that include genes that are not associated with a specific inherited disorder (ACOG, 2019). Furthermore, there is a lack of standardization in the genetic Panel composition, thus Panels for the similar conditions, may evaluate different set of genes. Currently, there are no existing professional guidelines to support the ordering and evaluation of Carrier screening by expanded Panels (Grody et al., 2013).

Additionally, for every disorder, the gene/mutation/mutation frequency should be known in the population being tested so that negative test results can be translated into an expected residual risk of the disorder (Grody et al., 2013). Unfortunately, many laboratories are unable to calculate the residual risk as they lack the knowledge of the carrier frequency within the testing population and the proportion of disease-causing mutations on the assay platform.

Genetic counseling is strongly recommended prior to these tests in order to inform persons being tested about the advantages and limitations of the test as applied to a unique person. For information regarding noninvasive prenatal screening (NIPT) for fetal aneuploidy, refer to the Medical Policy titled Fetal Aneuploidy Testing Using Cell-Free Fetal Nucleic Acids in Maternal Blood.

CLINICAL EVIDENCE

Ashkenazi Jewish Carrier Screening
Shi et al. (2017) genotyped over 3,000 individuals of self-reported Ashkenazi Jewish (AJ) ancestry to analyze the carrier frequency of 29 recessive genetic diseases to determine if additional disorders should be considered as part of routine carrier screening. The team reviewed the literature and the internal database at their lab to identify the genes that should be screened, and utilized pre-existing, de-identified samples from research participants. There were 2252 AJ individuals tested for 29 recessive disorders, and an additional 1390 AJ and 6813 non-AJ individuals were screened for a subset of 18 recessive disorders. The authors identified seven disorders with a carrier frequency of greater than 1 in 100, nine with a carrier frequency between 1 in 100 and 1 in 200, and four between 1 in 200 and 1 in 500. Nine conditions had a carrier frequency of less than 1 in 500 or were not found. Of the 20 diseases with a carrier frequency higher than 1 in 500, two were eye diseases that the authors felt were not appropriate to be included for reproductive related carrier screening. Of the remaining 18 disorders, the team calculated that the cumulative chance for an individual to be a carrier of one of the 18 diseases was 1 in 6. However, the chance that an AJ couple would be carriers of the same disease and be at risk for an affected pregnancy is 1 in 441.

Arjunan et al. (2016) at the Center for Jewish Genetics explored the difference between targeted mutation analysis for Tay Sachs disease, plus enzyme analysis, with next generation sequencing (NGS). Blood or saliva samples were collected on 506 individuals who underwent NGS for 84 recessive conditions and targeted genotyping. Two hundred and eighty-eight individuals were carriers of at least one condition, represented by 434 pathogenic variants, and eight couples were carriers for the same disorder. When NGS was compared to traditional screening for the diseases routinely screened for in the AJ population, NGS did not find any additional mutations beyond what would have been found by targeted genotyping. However, NGS and the broader panel identified two carrier at risk couples, and 115 (26%) pathogenic variants that would not be found by routine AJ screening.

Professional Societies
American College of Medical Genetics and Genomics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG)
The ACMG practice guideline from 2008, reaffirmed in 2013 (Gross, et al., 2008) and the ACOG Committee Opinion No. 691 from 2017, reaffirmed in 2019, both recommend carrier screening for Ashkenazi Jewish individuals for:
• Tay-Sachs disease (disease incidence 1/3000; carrier frequency 1/30);
• Canavan disease (1/6,400; 1/40); and
• Cystic fibrosis (1/2,500-3,000; 1/29); and
• Familial Dysautonomia (1/3,600; 1/32).

In addition, the ACMG practice guideline recommends that the following also be offered to all individuals of Ashkenazi Jewish descent who are pregnant, or considering pregnancy (Gross et al. 2008):
• Fanconi Anemia (group C) (1/32,000; 1/89)
• Niemann-Pick (type A) (1/32,000; 1/90)
• Bloom syndrome (1/40,000; 1/100)
• Mucolipidosis IV (1/62,500; 1/127)
• Gaucher disease (1/900; 1/15)
• Maple Syrup Urine Disease (1/50,000; 1/81)
• Joubert syndrome (1/33,000; 1 in 92)
• Glycogen storage disease 1A (1/20,000; 1/71)
• Familial hyperinsulinism (1/10,000; 1/52)

If only one member of the couple is Jewish, ideally, that individual should be tested first. One Jewish grandparent is sufficient to offer testing. If the Jewish partner has a positive carrier test result, the other partner (regardless of ethnic background) should be tested for variants associated with that particular disorder (Gross et al. 2008). ACOG similarly states that carrier screening for this disorder can be considered, as well as Usher syndrome, but notes that the prevalence of these disorders in non-Jewish populations is unknown and counseling prospective parents on residual risks when one partner is non-Jewish can be complicated.

**Expanded Carrier Screening**

Peyser et al. (2018) compared the efficiency of expanded carrier screening (ECS) to ethnic-based screening to identify carriers. A cohort of 4232 patients seeking fertility treatment was studied. ECS was performed at one genetic testing laboratory for patients seen between June 2013 and July 2015. Ethnicity was self-reported. Carrier status based on ECS was calculated. Carrier rates were also determined for the ACOG recommended ECS panel (ACMG-based screening) and ethnic-based screening (ACOG and ACMG ethnicity panel recommendations). The ECS utilized was made up of 400 variants of 102 genes associated with 100 genetic conditions. Fragile X CGG repeat size and the number of SMN1 exon 7 copy-number status to screen for spinal muscular atrophy were also included in the ECS. Carrier rates were calculated for the overall study population and for each ethnic subpopulation and then compared to determine differences between carrier identification rates by each panel. The ECS panel did not screen for α-thalassemia and maple syrup urine disease 1A (MSUD1A), 2 conditions included in the ACOG-based screening panel. Therefore, the carrier rate for the ACOG-based screening was calculated without including these two conditions. A total of 4232 patients were tested (2880 females [68.1%]; 1352 males [31.9%]) for carrier status using ECS. Applying ethnic based screening recommendations would have resulted in 359 out of 4232 (8.5%) patients identified as carriers. Upon applying the AGOC based screening guidelines, 659 out of 4232 (15.6%) would have been identified as carriers. With the ECS panel, 1243 (29.4%) of patients were identified as carriers. A large and highly significant difference was found between carrier rates when each panel was applied to the population and then compared to each other. The authors also looked at the data from subpopulations based on self-reported ethnicity. The number of carriers identified increased with the increasing panel size across the total study cohort and in all but 3 of 14 self-reported ethnicities. In the Southeast Asian and Native American populations, the only increase was seen from ACOG-based screening to ECS resulting in identification of additional carriers. However, the identification of carriers did not change regardless of the panel for Pacific Islander cohort. Further, looking at the overall population and five subpopulations, carrier rates were statistically different in all 3 comparisons: Mixed or Other Caucasian, Southern European, Northern European, Unknown/Not Reported, and Ashkenazi Jewish. In three subpopulations, that is Hispanic, South Asian, and Middle Eastern, significant differences were observed in ethnic-based screening versus ECS and ACOG-based ethnic screening versus ECS, but not the ethnic-base screening versus ACOG-based screening. Ethnic based screening versus ECS only provided statistical differences in the African or African American population. However, in 2 subethnic populations, East Asian and Southeast Asian, the carrier numbers for each panel were not statistically significant. A total of 1206 couples were screened using the ESC panel, 15 (1.2%) of which were identified as carrier couples. In revealing the ethnicity of each partner, 8 of 15 (53%) would have been recognized through ethnic-based screening guidelines. In addition to carrier couples, 73 women were found be carriers of Fragile X, with variation in repeat numbers identified and thus variation in classification of the reproductive risk. In conclusion, the authors present data that ECS is greater to ethnic-based genetic screening at identifying genetic disease carriers and carrier couples. The authors argue that their study provides additional evidence that ECS provides a larger amount of preconception information for patients.

Johansen et al. (2018) reported on a survey of the females from 1701 at risk couples (ARC) who participated in expanded carrier screening (ECS) of 176 genetic conditions. The cohort was identified from over 270,000 individuals who underwent screening via the laboratory’s ECS from September 1, 2015 to December 31, 2017. Females were identified from the database who (1) were found to be carriers of a pathogenic or likely pathogenic variant conferring risk for at least one of 176 autosomal recessive or X-linked conditions currently included in the labs ECS, (2) were aged 18 years or older, (3) had consented to being contacted about participating in research at the lab, and (4) for
those carrying pathogenic or likely pathogenic variants associated with autosomal recessive conditions, had reproductive partners meeting the same eligibility criteria and were confirmed by the lab as being carriers of a pathogenic variant in the same gene. Couples carrying only variants known to cause mild presentations of biotinidase deficiency (D444H), NPHS2-related nephrotic syndrome (R229Q), and 21-OH deficient congenital adrenal hyperplasia (CAH) (CYP21A2 gene duplication) were excluded. The 1701 ARC were geographically dispersed and comprised 15 ethnicities and over 9 religions. The ARC reported being at risk for 53 different conditions, with 10% indicating they were at risk for 2 conditions and 1.8% being at risk for 3 conditions. The actions taken by the ARC were broken down into those receiving preconception ECS results and those receiving the results during the prenatal period. ECS was performed on 235 preconception ARC, 77% of which indicated they planned or pursued pregnancy management options, of which 59% for in vitro fertilization (IVF) with preimplantation genetic diagnosis for monogenic/single gene disorders (PGT-M), 48% prenatal diagnosis, 18% donor gamete, 12% addition and 9 % no longer planning to get pregnant. Of the 154 ARCs who received the ECS results while pregnant, 37% pursued invasive prenatal testing (PNDx), of which 36% had affected pregnancies, and 40% of those resulted in termination. Of the 63% that did not have PNDx, 75% had given birth at the time of the survey and 44% of those planned or pursued postnatal diagnosis. In addition, 2.1% terminated the pregnancy without PNDx. The authors asked about actions in subsequent pregnancies. Of those who pursued PNDx through Chorionic villus sampling [CVS] or amniocentesis, 29% had affected fetuses, and 75% of those terminated their pregnancies. Limitations of the study included patient’s recall of actions possible response bias, and a larger number of ARCs whose current or future pregnancies were at risk for conditions that occur more often in the population such as cystic fibrosis. However, the authors tried to decrease these effects by analyzing results in aggregate and by condition severity. Overall, study represents largest cohort of ARCs to date and diverse couples screened for up to 176 conditions.

Shraga et al. (2018) reported on reliability self-reported ethnicity verses genetic ancestry for clinical decision-making in the context of genetic carrier screening. The 9138 participants were referred by a variety of healthcare providers such as fertility specialists, obstetricians/gynecologists, and genetic counselors from the United States and Spain. The carrier screening test consisted of 311 autosomal recessive and X-linked conditions. Ethnicity information was gathered two times, first at the time the test was ordered, and second when self-recorded on the test requisition form. The couples were asked to choose all applicable ethnicities from the following list of options: African, East Asian, European, French Canadian, Jewish, Latin American, Mediterranean, Middle Eastern, Native American, South Asian, Southeast Asian, Other. For the option “Other”, people could write in the self-identified ethnicity. All responses were mapped to appropriate categories when applicable, i.e., Caucasian/White mapped to European. The second self-report was obtained during the post-test appointment with a genetic counselor. During the family history portion of the consultation, individuals were asked to identify their race/ethnicity or where their family originated from. For situations where patients did not participate in counseling or were unreachable, a “family history” ethnicity was not generated, and the patients were not considered in that part of the analysis. However, they were still included in the comparison between “requisition form” ethnicity and genetic ancestry. A set of single nucleotide polymorphisms (SNPs) was selected that could accurately determine continental genetic ancestry in the patient population. SNP frequencies were obtained from the ALFRED database, and through a repetitive process, a set of SNPs that could separate the continental groups was selected. Six of the eight continental groups were determined to be well separated. The Middle Eastern and Central Asian groups are closely related to the European and South Asian groups, respectively, and require an extra set of markers to properly estimate population separations. For this reason, it was decided not to use these two groups as separate ancestral populations and removed them from the ultimate estimation. The authors also validated the genetic ancestry model by applying a set of 2504 samples with known origin from the 1000 Genomes project. This test showed the set of 1142 SNPs was able to correctly estimate continental ancestry in the included populations. The results also validate the approach of using pre-committed population allele frequencies. A comparison of the self-reports in the two situations was then performed. First, the ethnicity reported on the requisition form was compared to that provided during the genetic counseling session. For each ethnic group, counts were generated for: 1) each patient who selected it on the requisition form, 2) each patient who identified it during consultations, and 3) each patient who did both. Patient who selected “Other” on the requisition form were excluded. Consistent patterns were seen in self-reported identification in both situations. For example, 97.7% of patients that selected East Asian on the requisition form identified as have East Asian during the genetic counseling session, while 99.2% of patients identified having East Asian ancestry during the consult also selected East Asian on the requisition form. However, for ethnicities such as Mediterranean, Native American, and Southeast Asian, the responses between the two sources of self-report were different. Another observed difference was between self-reported ethnicity on the requisition form and genetic ancestry in South Asians and Southeast Asians. However, these differences were diminished when obtaining ethnicity during the genetic counseling session. The differences indicate that there is confusion about the meaning of different labels, indicating that self-reporting of ethnicity cannot be relied upon. When calculating genetic reproductive risk, inaccurate reporting of ethnicity results in inaccurate calculation of risk. Admixed populations were also looked at, and results indicate that carrier rates and residual risks are dependent on genetic ancestry in these populations. For example, in the carrier rate for cystic fibrosis varies from 1.6% to 3.67% in the Latin American population depending on the percent of European ancestry, and the carrier rate for sickle cell anemia varies from 1.3% to 4.6% depending on the amount of African ancestry. Thus, it cannot be assumed that the genetic risk to admixed populations occurs in a consistent manner. The source of ethnic background can have an

Carrier Testing for Genetic Diseases
UnitedHealthcare Commercial Medical Policy

Proprietary Information of UnitedHealthcare. Copyright 2019 United HealthCare Services, Inc.
impact on estimating carrier and recurrence risk and providing appropriate testing, and impact decision making. Thus, the authors suggest in order to mitigate these risks and ensure serious genetic disorders are not missed; expanded carrier screening panels should be utilized. Despite the disadvantages of expanded carrier panels, given that self-reporting of ethnicity is unreliable and can lead to providing an incomplete picture of risks to couples, the expanded carrier screens provide a comprehensive approach. The authors also concluded that genetic ancestry should be determined by appropriate clinical testing rather than self-report in order to provide accurate carrier rates, detection rates and residual risks based on self-reported ethnicity. The retrospective nature of this study is one of its limitations. Another is that self-reported ethnicity could have been incorrectly entered in the database or modified. A third limitation is the ancestry model used is based on allele frequencies estimates from small sample size and assumes that assembling people by continent provides meaningful estimates of origin. Additional studies with larger cohorts are needed to improve the ancestry model and to measure the relationship between carrier rates and genetic ancestry for more diseases. Additional work is needed to understand the factors leading to self-identified ethnicity. In conclusion, self-reported ethnicity is shown to be unreliable, leading to the possibility of inaccurate calculation of carrier rates and residual risk. To decrease the risk of ordering the incorrect testing panel, the authors recommend the use of expanded pan-ethnic carrier screening panels. In addition, in order to accurately estimate carrier rates and residual risks, they recommend the use of a genetic ancestry model in clinical genetic testing.

Terhaar et al. (2018) retrospectively report on their experience as a commercial laboratory with reproductive carrier screening comparing three panels; 3 genes, 23 genes, or 218 genes. Data was assessed on 75,036 individuals referred by a healthcare provider in the United States. Three genes were assessed in 51,584 samples, and 7.2% had a positive result. The 23 gene panel was assessed for 19,550 samples, and 13.2% were positive. Finally, 3,902 samples were assessed for 218 genes, and 36% were positive. Overall, 127 conditions came up positive at least once in this group. The authors noted that those that seeking the 218 gene panel were more ethnically diverse when compared to the other groups. It was not reported in this study if any at risk couples were identified. In addition, it was noted that while receiving more genomic information can be beneficial to patients and providers who want a lot of information to inform medical management, this may also place a burden on clinical care. Most of the disorders identified were inherited in a recessive manner, requiring the clinicians to provide counseling and screening for a reproductive partner. Large panels may identify conditions with mild phenotypes. Common diseases like cystic fibrosis may be familiar to clinicians, but rare diseases may not. Educational resources for clinicians and patients are needed in order to ensure informed conversations and decision making.

Wilfond et al. (2018) reported on lessons learned from the NextGen study, a prospective study designed to explore the best approaches to genomic based reproductive carrier screening. The study randomized women who saw a genetic counselor in person who desired carrier screening, and randomized them to those that received genomic sequencing (n=133) and those who received usual care-meaning no additional screening (n=180). If a woman was positive, her male partner was offered genome sequencing to determine the risk of having an affected pregnancy. In the genome sequencing arm, the team chose to report on 728 conditions, and categorized the conditions into five classes that participants could choose to learn about or not. The classes included diseases with a shortened life span, serious conditions, mild conditions, conditions with unpredictable outcomes, adult onset conditions, and medically actionable conditions related to the individual’s personal health (secondary to carrier screening.) Overall, 15 at risk couples were identified, and most were for adult onset conditions. Eight were at risk for hereditary hemochromatosis, two for alpha-1-antitrypsin deficiency; one for non-syndromic hearing loss, one for Factor V Leiden homozygous offspring, and the remaining were for X-linked disorders. These included spondyloepiphyseal dysplasia, G6PD deficiency, and hemophilia A. Overall, however, 78% of participants had at least one finding. This leads to concerns about implementation of this approach into clinic workflows. The median time needed to prepare for a follow up visit for positive results disclosure by a genetic counselor was 64 minutes. In this study, 26% of women became pregnant before disclosure, adding additional time sensitivity to developing a genomic based screening program. The authors noted that their study design and size did not allow for a complete analysis of clinical utility, but they highlighted some anecdotal evidence that was collected. It was reported that women did not seek out more mental health or other services compared to those receiving usual care. They did not report more anxiety or depression. One participant declined amniocentesis for chromosome abnormalities because she believed the expanded carrier screening covered that, and this misconception was later corrected. The woman identified as a carrier of hemophilia A did undergo an amniocentesis, and the fetus was male and found to carry the pathogenic variant. This altered the birth plan and allowed the neonatal team to intervene early. The baby did experience a rare subgaleal hemorrhage after birth, which was immediately treated. Finally, the authors noted that their study was small and on an older, more educated population. When asked about what they might pay out of pocket for genome sequencing, participants were willing to pay a little more than a copay, but the amount varied based on income. In conclusion, the authors noted that genomic sequencing as an approach to routine carrier screening could have significant impact on clinical workflow and resources, the optimal gene targets need to be identified, and may not be accessible to low income patients. Additional research is needed to address these issues.

Ghiossi et al. (2017) studied the decision making of 537 couples who were identified to be carriers of the same genetic disease after undergoing expanded carrier screening for 110 genes through their commercial lab. These
couples represented 1% of 51,775 couples screened between August 2014 and August 2015. The diseases included in the study were classified to be profound, severe, or moderate in terms of clinical impact. All couples were invited to participate in a survey about reproductive decision making, and 64 completed the survey. Of these, 45 couples had sought screening prior to pregnancy, and 62% reported that they planned to use preimplantation genetic diagnosis or prenatal diagnosis in a future pregnancy. Twenty-nine percent did not plan to alter reproductive decision making and the remaining four survey responses were unclear. Of the 19 pregnant couples, 10 elected to have prenatal diagnosis but two miscarried before testing could occur. Of those that had testing, five pregnancies were unaffected, and three were affected. Two affected pregnancies were terminated. The remaining couples did not think the condition they were at risk for was significant enough to undergo invasive testing. Perceived severity of the disorder appeared to impact decision making, as 76% of couples who were at risk for a profound or severe disorder reported altering reproductive decision making as a result, compared to only 22% of those at risk for moderate conditions. The authors also compared the choices made by the couples by diseases in professional society screening guidelines (20 couples) and diseases not currently in guidelines (22 couples), and found no significant difference in decision making. The authors noted that limitations of the study included the low response rate, lack of random sampling, and possible response bias.

Haque, et al. (2016) created a model of fetal risk based on a commercial laboratories experience with expanded carrier screening. From January 2012 to July 2015, the laboratory screened 346,790 individuals that were referred for testing by their healthcare provider. The expanded carrier screening test offered was for 110 genes, including 94 conditions categorized as severe or profound. Two platforms were utilized. The first was a targeted genotyping platform for 417 known pathogenic variants, and the second was next generation sequencing for all genes. Healthcare providers could select the testing platform and genes desired for their patient, so not all patients were screened for all conditions. Targeted genotyping was performed on 308,668 patients, and 47,590 carriers were identified, and 279 individuals were homozygous or compound heterozygotes. Next generation sequencing was completed on 38,122 individuals, and 11,088 people were carriers, and 124 were identified as homozygous or compound heterozygous. Results were reviewed in the context of the participant gender and self-reported race/ethnicity. The largest racial mix in the study was "mixed or other Caucasian." The smallest group included in the analysis was SE Asian, although Finnish was the smallest overall and excluded from the final analysis due to small numbers. The authors utilized the results of both platforms to estimate the carrier frequency by ethnic group, and then modeled the carrier frequency, carrier couple frequency for couples of the same ethnicity, and resulting fetal risk. Based on the model, the authors then compared the detection rate of potential at risk couples for diseases included in current professional carrier screening guidelines against the detection rate of all profound and severe diseases in the expanded carrier screening panel. When hemoglobinopathy genes are excluded from analysis, African Americans were noted to have 18% of profound or severe recessive diseases covered by guidelines, and 82% were outside of guidelines, with a calculated cumulative risk of 1 in 1,741 to have a fetus affected by any profound/severe condition in the study. The Ashkenazi Jewish group had 45% within guidelines, and 55% outside of guidelines with a modeled fetal risk on 1 in 255. Mixed or other Caucasian had 32% within guidelines, and 68% outside of guidelines with a modeled fetal risk on 1 in 649. The authors conclude that current guidelines do not perform equally well between self-reported ethnic groups, and currently target diseases prevalent in European populations. Expanded carrier screening may identify couples at risk for other conditions that are important in a diverse population. Limitations identified for the study includes the use of an artificial construct to calculate disease frequencies and fetal resulting from random mating within an ethnic group. Disease frequencies in the general population might vary when compared to the population referred for genetic testing by a healthcare provider. The model doesn't fully address the racial/ethnic admixture possible in the study population or in real world reproductive pairing. Prospective studies comparing current standard of care with expanded carrier screening are needed before expanded carrier screening is fully adopted.

Professional Societies

American College of Obstetricians and Gynecologists (ACOG)
In their 2017 Committee Opinion 690, ACOG states that if an expanded carrier screening test is to be considered, the following consensus driven criteria should be considered:

- Have a carrier frequency greater than 1 in 100
- The condition should have a well defined phenotype, a detrimental effect on quality of life, cause physical or cognitive impairment, and have onset early in life
- Can be diagnosed prenatally to provide opportunities for antenatal intervention to improve perinatal outcomes such as changes in delivery management, and to educate parents about special needs after birth
- Carrier screening panels should not include adult onset conditions

American College of Medical Genetics and Genomics (ACMG)
An ACMG position statement states that although some commercial laboratories offer expanded carrier screening panels, there is little consensus on which disease genes and mutations to include in these panels (Grody et al., 2013; Edwards et al., 2015). Panels for that include multiple carrier screening tests may be useful if they include the diseases that are present with increased frequency in a specific population (i.e., Ashkenazi Jewish Carrier Screening),
but do not have clinical utility when they include a larger number of genetic diseases for which the individual does not have an increased risk of being a carrier.

**U.S. FOOD AND DRUG ADMINISTRATION (FDA)**


**CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)**

Medicare does not have a National Coverage Determination (NCD) that specifically addresses Ashkenazi Jewish carrier screening or any expanded carrier screening panel testing (for other indications). Local Coverage Determinations (LCDs) exist, see the LCDs for Biomarkers Overview, Molecular Diagnostic Tests (MDT), MolDX: Molecular Diagnostic Tests (MDT) and Molecular Pathology Procedures. (Accessed May 31, 2019)

**REFERENCES**


POLICY HISTORY/REVISION INFORMATION

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/01/2019</td>
<td><strong>Related Policies</strong>&lt;br&gt;• Added reference link to the Medical Policy titled <em>Preimplantation Genetic Testing</em>&lt;br&gt;<strong>Coverage Rationale</strong>&lt;br&gt;• Simplified content&lt;br&gt;<strong>Definitions</strong>&lt;br&gt;• Added definition of:&lt;br&gt;  o Carrier Screening&lt;br&gt;  o Expanded Carrier Panel Screening&lt;br&gt;  o Panel&lt;br&gt;<strong>Supporting Information</strong>&lt;br&gt;• Updated <em>Description of Services, Clinical Evidence, CMS, and References</em> sections to reflect the most current information&lt;br&gt;• Archived previous policy version 2019T0586E</td>
</tr>
</tbody>
</table>

INSTRUCTIONS FOR USE

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence (*Medicare IOM Pub. No. 100-16, Ch. 4, §90.5*).

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.